High-Grade Glioma - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 162 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma – Pipeline Review, H2 2016, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated appetite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
High-Grade Glioma Overview 9
Therapeutics Development 10
Pipeline Products for High-Grade Glioma - Overview 10
Pipeline Products for High-Grade Glioma - Comparative Analysis 11
High-Grade Glioma - Therapeutics under Development by Companies 12
High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes 14
High-Grade Glioma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
High-Grade Glioma - Products under Development by Companies 18
High-Grade Glioma - Products under Investigation by Universities/Institutes 19
High-Grade Glioma - Companies Involved in Therapeutics Development 20
Advenchen Laboratories LLC 20
AngioChem Inc 21
Arog Pharmaceuticals Inc 22
Astellas Pharma Inc 23
Athenex Inc 24
Bayer AG 25
BTG Plc 26
Cavion LLC 27
CBT Pharmaceuticals Inc 28
DelMar Pharmaceuticals Inc 29
Merrimack Pharmaceuticals Inc 30
Millennium Pharmaceuticals Inc 31
Nektar Therapeutics 32
Novartis AG 33
Sanofi 34
Sumitomo Dainippon Pharma Co Ltd 35
Targepeutics Inc 36
Tocagen Inc 37
Virttu Biologics Ltd 38
ZIOPHARM Oncology Inc 39
High-Grade Glioma - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
AdRTSIL-12 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
alisertib - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
apatinib - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
bendamustine hydrochloride - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
BMX-001 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
cabazitaxel - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
CBT-101 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Cellular Immunotherapy for Gliomas - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Cellular Immunotherapy for High-Grade Glioma - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Cellular Immunotherapy for Oncology - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
crenolanib besylate - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
dabrafenib mesylate - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
dianhydrogalactitol - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
DSP-7888 - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
etirinotecan pegol - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
flucytosine + TBio-01 - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
flucytosine ER + vocimagene amiretrorepvec - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
GB-13 - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
HSV-1716 - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
irinotecan hydrochloride - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
irinotecan hydrochloride + TBio-02 - Drug Profile 134
Product Description 134
Mechanism Of Action 134
R&D Progress 134
irinotecan hydrochloride CR - Drug Profile 135
Product Description 135
Mechanism Of Action 135
R&D Progress 135
KX-02 - Drug Profile 136
Product Description 136
Mechanism Of Action 136
R&D Progress 136
mibefradil dihydrochloride - Drug Profile 138
Product Description 138
Mechanism Of Action 138
R&D Progress 138
Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile 141
Product Description 141
Mechanism Of Action 141
R&D Progress 141
paclitaxel trevatide - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
RRX-001 - Drug Profile 147
Product Description 147
Mechanism Of Action 147
R&D Progress 147
sorafenib tosylate - Drug Profile 149
Product Description 149
Mechanism Of Action 149
R&D Progress 149
High-Grade Glioma - Dormant Projects 156
High-Grade Glioma - Discontinued Products 157
High-Grade Glioma - Product Development Milestones 158
Featured News & Press Releases 158
Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma 158
May 28, 2015: Cavion to Present Clinical Trial Data at ASCO 159
May 31, 2014: Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting 159
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 161
Disclaimer 162

List of Tables

Number of Products under Development for High-Grade Glioma, H2 2016 10
Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H2 2016 20
High-Grade Glioma - Pipeline by AngioChem Inc, H2 2016 21
High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H2 2016 22
High-Grade Glioma - Pipeline by Astellas Pharma Inc, H2 2016 23
High-Grade Glioma - Pipeline by Athenex Inc, H2 2016 24
High-Grade Glioma - Pipeline by Bayer AG, H2 2016 25
High-Grade Glioma - Pipeline by BTG Plc, H2 2016 26
High-Grade Glioma - Pipeline by Cavion LLC, H2 2016 27
High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H2 2016 28
High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H2 2016 29
High-Grade Glioma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 30
High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 31
High-Grade Glioma - Pipeline by Nektar Therapeutics, H2 2016 32
High-Grade Glioma - Pipeline by Novartis AG, H2 2016 33
High-Grade Glioma - Pipeline by Sanofi, H2 2016 34
High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 35
High-Grade Glioma - Pipeline by Targepeutics Inc, H2 2016 36
High-Grade Glioma - Pipeline by Tocagen Inc, H2 2016 37
High-Grade Glioma - Pipeline by Virttu Biologics Ltd, H2 2016 38
High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H2 2016 39
Assessment by Monotherapy Products, H2 2016 40
Assessment by Combination Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 46
Number of Products by Stage and Route of Administration, H2 2016 48
Number of Products by Stage and Molecule Type, H2 2016 50
High-Grade Glioma - Dormant Projects, H2 2016 156
High-Grade Glioma - Discontinued Products, H2 2016 157